♥
ISIN : INE767A01016
NSE : AARTIDRUGS
BSE : 524348
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 18.56
EPS (TTM) : 16.59
Price to Earning (P/E) : 18.34
Book Value : 139.40
Price to Bookvalue (P/B) : 2.44
Dividend Yield : 0 %
Return on Equity (ROE) : 13.87 %
Return on Capital Employed (ROCE) : 15.01 %
Aarti Drugs Limited
ISIN : INE767A01016
NSE : AARTIDRUGS
BSE : 524348
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : 18.56
EPS (TTM) : 16.59
Price to Earning (P/E) : 18.34
Book Value : 139.40
Price to Bookvalue (P/B) : 2.44
Dividend Yield : 0 %
Return on Equity (ROE) : 13.87 %
Return on Capital Employed (ROCE) : 15.01 %
Aarti Drugs share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 345 - 352.05 2 % |
| Low / High | 334.4 - 354 5.9 % |
| Trade Volume | 8,332 |
| 52 Week Low / High | 318.6 - 574.95 80.5 % |
-
YOU MAY ALSO LIKE
- Share Market basics for beginners
Share Market jargons in simple terms - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - Stock market course tutorial
Stock Market Investment Course explained in simple words. - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE
CONSOLIDATED QUARTERLY RESULT FOR AARTI DRUGS LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 6219.6 | 6877.2 | 6639.6 | 7424.1 | 6611.1 | 6415.4 | 6059.4 | 6199.9 | 5553.4 | 5983.3 |
| Total Income | 6222.2 | 6877.8 | 6649.7 | 7432.8 | 6617.1 | 6422.2 | 6076.1 | 6210.7 | 5564.5 | 5998.1 |
| Total Expenditure | 5548.2 | 6134.5 | 5933.1 | 6488.7 | 5770.4 | 5650.9 | 5358 | 5341.8 | 4903.8 | 5312.8 |
| Other Income | 2.6 | 0.6 | 10.1 | 8.7 | 6 | 6.8 | 16.7 | 10.8 | 11.1 | 14.8 |
| Operating Profit | 674 | 743.3 | 716.6 | 944.1 | 846.7 | 771.3 | 718.1 | 868.9 | 660.7 | 685.3 |
| Interest | 68.3 | 84.7 | 93.6 | 86.3 | 85.4 | 82.5 | 76 | 91.3 | 87.1 | 89.3 |
| PBDT | 605.7 | 658.6 | 623 | 857.8 | 761.3 | 688.8 | 642.1 | 777.6 | 573.6 | 596 |
| Depreciation | 125.4 | 126.6 | 126.2 | 125 | 126 | 126.1 | 126.6 | 135.8 | 133.8 | 137.2 |
| Profit Before Tax | 480.3 | 532 | 496.8 | 732.8 | 635.3 | 562.7 | 515.5 | 641.8 | 439.8 | 458.8 |
| Tax | 132.5 | 144.6 | 130.1 | 171 | 155.6 | 166.7 | 148.4 | 168.7 | 107.1 | 109.2 |
| Profit After Tax | 347.8 | 387.4 | 366.7 | 561.8 | 479.7 | 396 | 367.1 | 473.1 | 332.7 | 349.6 |
| Net Profit | 347.8 | 387.4 | 366.7 | 561.8 | 479.7 | 396 | 367.1 | 473.1 | 332.7 | 349.6 |
| Equity Capital | 926 | 926 | 926 | 926 | 926 | 919.4 | 919.4 | 919.4 | 919.4 | 912.7 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | 3.76 | 4.18 | 3.96 | 6.06 | 5.17 | 4.31 | 3.99 | 5.15 | 3.62 | 3.84 |
| Diluted Eps After Extraordinary Items | 3.76 | 4.18 | 3.96 | 6.07 | 5.18 | 4.29 | 3.99 | 5.15 | 3.62 | 3.83 |
| Diluted Eps Before Extraordinary Items | 3.76 | 4.18 | 3.96 | 6.07 | 5.18 | 4.29 | 3.99 | 5.15 | 3.62 | 3.83 |
STANDALONE QUARTERLY RESULT FOR AARTI DRUGS LIMITED
| Date End | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 5512 | 6248.3 | 6255.3 | 6964.1 | 5916.3 | 5775.4 | 5382.1 | 5595.3 | 4929.6 | 5430.9 |
| Total Income | 5514.4 | 6249.2 | 6265 | 6973.4 | 5922.8 | 5782.8 | 5398.9 | 5606.4 | 4930.7 | 5434.7 |
| Total Expenditure | 4964.7 | 5546.5 | 5565.5 | 6078.9 | 5197.2 | 5121.2 | 4784.7 | 4904.7 | 4387.4 | 4835.5 |
| Other Income | 2.4 | 0.9 | 9.7 | 9.3 | 6.5 | 7.4 | 16.8 | 11.1 | 1.1 | 3.8 |
| Operating Profit | 549.7 | 702.7 | 699.5 | 894.5 | 725.6 | 661.6 | 614.2 | 701.7 | 543.3 | 599.2 |
| Interest | 67.9 | 82.7 | 91.2 | 83.5 | 77.7 | 75.5 | 67.5 | 80.9 | 74.6 | 71.7 |
| PBDT | 481.8 | 620 | 608.3 | 811 | 647.9 | 586.1 | 546.7 | 620.8 | 468.7 | 527.5 |
| Depreciation | 118.3 | 119.2 | 118.7 | 116.8 | 117.5 | 117.8 | 118 | 123.4 | 117.1 | 118.6 |
| Profit Before Tax | 363.5 | 500.8 | 489.6 | 694.2 | 530.4 | 468.3 | 428.7 | 497.4 | 351.6 | 408.9 |
| Tax | 100 | 135 | 122.5 | 162.5 | 135 | 122.5 | 112.5 | 136 | 82.5 | 105 |
| Profit After Tax | 263.5 | 365.8 | 367.1 | 531.7 | 395.4 | 345.8 | 316.2 | 361.4 | 269.1 | 303.9 |
| Net Profit | 263.5 | 365.8 | 367.1 | 531.7 | 395.4 | 345.8 | 316.2 | 361.4 | 269.1 | 303.9 |
| Equity Capital | 926 | 926 | 926 | 926 | 926 | 919.4 | 919.4 | 919.4 | 919.4 | 912.7 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Calculated EPS | 2.85 | 3.95 | 3.96 | 5.74 | 4.27 | 3.76 | 3.44 | 3.93 | 2.93 | 3.33 |
| Diluted Eps After Extraordinary Items | 2.85 | 3.95 | 3.96 | 5.74 | 4.27 | 3.75 | 3.44 | 3.93 | 2.93 | 3.33 |
| Diluted Eps Before Extraordinary Items | 2.85 | 3.95 | 3.96 | 5.74 | 4.27 | 3.75 | 3.44 | 3.93 | 2.93 | 3.33 |
CONSOLIDATED ANNUAL RESULT FOR AARTI DRUGS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 24886.5 | 27160.5 | 25285.8 |
| Total Income | 24999.6 | 27182.5 | 25326.1 |
| Total Expenditure | 21592 | 24104.6 | 22121.1 |
| Other Income | 113.1 | 22 | 40.3 |
| Operating Profit | 3407.6 | 3077.9 | 3205 |
| Interest | 207.5 | 332.9 | 335.2 |
| PBDT | 3200.1 | 2745 | 2869.8 |
| Depreciation | 500.5 | 503.2 | 514.5 |
| Profit Before Tax | 2699.6 | 2241.8 | 2355.3 |
| Tax | 649.6 | 578.2 | 639.4 |
| Profit After Tax | 2050 | 1663.6 | 1715.9 |
| Net Profit | 2050 | 1663.6 | 1715.9 |
| Equity Capital | 926 | 926 | 919.4 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Calculated EPS | 22.14 | 17.96 | 18.64 |
| Diluted Eps After Extraordinary Items | 22.12 | 17.97 | 18.56 |
| Diluted Eps Before Extraordinary Items | 22.12 | 17.97 | 18.56 |
STANDALONE ANNUAL RESULT FOR AARTI DRUGS LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 22511.7 | 24979.7 | 22669.1 |
| Total Income | 22559.5 | 25002 | 22710.9 |
| Total Expenditure | 19330 | 22155.7 | 20007.8 |
| Other Income | 47.8 | 22.3 | 41.8 |
| Operating Profit | 3229.5 | 2846.3 | 2703.1 |
| Interest | 200.6 | 325.3 | 301.6 |
| PBDT | 3028.9 | 2521 | 2401.5 |
| Depreciation | 473.9 | 472.9 | 476.7 |
| Profit Before Tax | 2555 | 2048.1 | 1924.8 |
| Tax | 605 | 520 | 506 |
| Profit After Tax | 1950 | 1528.1 | 1418.8 |
| Net Profit | 1950 | 1528.1 | 1418.8 |
| Equity Capital | 926 | 926 | 919.4 |
| Face Value (IN RS) | 10 | 10 | 10 |
| Calculated EPS | 21.06 | 16.5 | 15.43 |
| Diluted Eps After Extraordinary Items | 21.04 | 16.5 | 15.35 |
| Diluted Eps Before Extraordinary Items | 21.04 | 16.5 | 15.35 |
CONSOLIDATED PROFIT / LOSS FOR AARTI DRUGS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 2154.78 Cr | 2488.65 Cr | 2716.05 Cr | 2528.58 Cr |
| Sales | 2154.78 Cr | 2488.65 Cr | 2716.05 Cr | 2508.87 Cr |
| Net Sales | 2154.78 Cr | 2488.65 Cr | 2716.05 Cr | 2528.58 Cr |
| Increase/Decrease in Stock | -11.72 Cr | -86.08 Cr | -1.75 Cr | 25.51 Cr |
| Raw Material Consumed | 1275.07 Cr | 1700.57 Cr | 1815.31 Cr | 1579.64 Cr |
| Opening Raw Materials | 122.21 Cr | 199.32 Cr | 221.62 Cr | 196.85 Cr |
| Purchases Raw Materials | 1240.93 Cr | 1614.31 Cr | 1669.24 Cr | 1485.84 Cr |
| Closing Raw Materials | 199.32 Cr | 221.62 Cr | 196.85 Cr | 183.28 Cr |
| Other Direct Purchases / Brought in cost | 111.24 Cr | 108.57 Cr | 121.29 Cr | 80.23 Cr |
| Power & Fuel Cost | 98.2 Cr | 128.48 Cr | 156.1 Cr | 154.31 Cr |
| Electricity & Power | 95.55 Cr | 125.86 Cr | 152.98 Cr | 150.85 Cr |
| Employee Cost | 65.88 Cr | 69.47 Cr | 80.37 Cr | 90.6 Cr |
| Salaries, Wages & Bonus | 62.38 Cr | 65.71 Cr | 76.56 Cr | 86.79 Cr |
| Contributions to EPF & Pension Funds | 2.17 Cr | 2.38 Cr | 2.31 Cr | 2.42 Cr |
| Workmen and Staff Welfare Expenses | 1.33 Cr | 1.38 Cr | 1.5 Cr | 1.39 Cr |
| Other Manufacturing Expenses | 181.4 Cr | 230.25 Cr | 241.58 Cr | 252.91 Cr |
| Processing Charges | 67.13 Cr | 79.29 Cr | 75.98 Cr | 83.63 Cr |
| Repairs and Maintenance | 10.43 Cr | 12.98 Cr | 21.11 Cr | 18.65 Cr |
| Packing Material Consumed | 35.59 Cr | 49.49 Cr | 48.4 Cr | 46.45 Cr |
| General and Administration Expenses | 29.03 Cr | 30.42 Cr | 28.31 Cr | 29.5 Cr |
| Insurance | 7.04 Cr | 7.88 Cr | 7.2 Cr | 7.68 Cr |
| Printing and stationery | 8.98 Lk | 16.26 Lk | 19.56 Lk | 21.04 Lk |
| Professional and legal fees | 5.55 Cr | 6.34 Cr | 5.66 Cr | 5.59 Cr |
| Traveling and conveyance | 71.21 Lk | 1.36 Cr | 2.02 Cr | 2.55 Cr |
| Selling and Distribution Expenses | 70.99 Cr | 73.99 Cr | 76.01 Cr | 63.79 Cr |
| Advertisement & Sales Promotion | 98.05 Lk | 1.35 Cr | 1.17 Cr | 2.33 Cr |
| Sales Commissions & Incentives | 22.66 Cr | 14.63 Cr | 19.4 Cr | 13.4 Cr |
| Freight and Forwarding | 41.42 Cr | 52.53 Cr | 45.59 Cr | 40.12 Cr |
| Handling and Clearing Charges | 5.93 Cr | 5.49 Cr | 5.58 Cr | 5.99 Cr |
| Miscellaneous Expenses | 5.54 Cr | 8.95 Cr | 10.67 Cr | 11.48 Cr |
| Bad debts /advances written off | 84.68 Lk | 1.69 Cr | 1.53 Cr | 1.9 Cr |
| Loss on disposal of fixed assets(net) | 0 | 0 | 0 | 18.34 Lk |
| Total Expenditure | 1714.4 Cr | 2156.05 Cr | 2406.6 Cr | 2207.74 Cr |
| Other Income | 4.53 Cr | 11.32 Cr | 2.19 Cr | 4.03 Cr |
| Interest Received | 2.6 Cr | 71.69 Lk | 69.92 Lk | 2.5 Cr |
| Dividend Received | 1.02 Cr | 1.6 Cr | 24,000 | 11,000 |
| Operating Profit | 444.9 Cr | 343.91 Cr | 311.64 Cr | 324.86 Cr |
| Interest | 26.23 Cr | 23.91 Cr | 37.14 Cr | 37.89 Cr |
| Interest on Term Loan | 16.52 Cr | 11.7 Cr | 9.93 Cr | 6.13 Cr |
| Bank Charges etc | 3.27 Cr | 3.16 Cr | 3.84 Cr | 4.37 Cr |
| PBDT | 418.67 Cr | 320 Cr | 274.51 Cr | 286.98 Cr |
| Depreciation | 49.88 Cr | 50.05 Cr | 50.32 Cr | 51.45 Cr |
| Profit Before Taxation & Exceptional Items | 368.79 Cr | 269.96 Cr | 224.18 Cr | 235.53 Cr |
| Exceptional Income / Expenses | 22.48 Lk | 0 | 0 | 0 |
| Profit Before Tax | 369.01 Cr | 269.96 Cr | 224.18 Cr | 235.53 Cr |
| Provision for Tax | 88.62 Cr | 64.96 Cr | 57.82 Cr | 63.94 Cr |
| Current Income Tax | 93 Cr | 69.74 Cr | 58.86 Cr | 59.56 Cr |
| Deferred Tax | -4.46 Cr | -4.78 Cr | -1.03 Cr | 4.37 Cr |
| Profit After Tax | 280.4 Cr | 205 Cr | 166.36 Cr | 171.59 Cr |
| Minority Interest | 1.47 Lk | 4.28 Lk | -4.84 Lk | -17.25 Lk |
| Consolidated Net Profit | 280.41 Cr | 205.04 Cr | 166.31 Cr | 171.42 Cr |
| Profit Balance B/F | 591.94 Cr | 753.8 Cr | 878.75 Cr | 1020.53 Cr |
| Appropriations | 872.36 Cr | 958.84 Cr | 1045.06 Cr | 1191.95 Cr |
| General Reserves | 25.77 Cr | 19.5 Cr | 15.28 Cr | 14.19 Cr |
| Other Appropriation | 69.49 Cr | 51.33 Cr | -1.76 Lk | 13.32 Cr |
| Equity Dividend % | 25 | 10 | 10 | 10 |
| Earnings Per Share | 30.09 | 22.14 | 17.96 | 18.65 |
| Adjusted EPS | 30.09 | 22.14 | 17.96 | 18.65 |
STANDALONE PROFIT / LOSS FOR AARTI DRUGS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 1914.89 Cr | 2251.17 Cr | 2497.97 Cr | 2266.91 Cr |
| Sales | 1914.89 Cr | 2251.17 Cr | 2497.97 Cr | 2253.74 Cr |
| Net Sales | 1914.89 Cr | 2251.17 Cr | 2497.97 Cr | 2266.91 Cr |
| Increase/Decrease in Stock | -9.08 Cr | -77.94 Cr | -6.72 Cr | 26.77 Cr |
| Raw Material Consumed | 1131.17 Cr | 1534.2 Cr | 1697.17 Cr | 1452.61 Cr |
| Opening Raw Materials | 113.36 Cr | 186.52 Cr | 205.93 Cr | 183.53 Cr |
| Purchases Raw Materials | 1161.16 Cr | 1495.29 Cr | 1627.76 Cr | 1402.38 Cr |
| Closing Raw Materials | 186.52 Cr | 205.93 Cr | 183.53 Cr | 169.16 Cr |
| Other Direct Purchases / Brought in cost | 43.17 Cr | 58.31 Cr | 47.01 Cr | 35.86 Cr |
| Power & Fuel Cost | 95.64 Cr | 126.05 Cr | 153.45 Cr | 151.64 Cr |
| Electricity & Power | 92.99 Cr | 123.44 Cr | 150.33 Cr | 148.18 Cr |
| Employee Cost | 55.6 Cr | 57.17 Cr | 64.25 Cr | 70.2 Cr |
| Salaries, Wages & Bonus | 52.3 Cr | 53.6 Cr | 60.62 Cr | 66.59 Cr |
| Contributions to EPF & Pension Funds | 2.17 Cr | 2.38 Cr | 2.31 Cr | 2.42 Cr |
| Workmen and Staff Welfare Expenses | 1.14 Cr | 1.2 Cr | 1.32 Cr | 1.19 Cr |
| Other Manufacturing Expenses | 155.21 Cr | 194.14 Cr | 207.43 Cr | 213.77 Cr |
| Processing Charges | 61.67 Cr | 72.84 Cr | 70.83 Cr | 76.27 Cr |
| Repairs and Maintenance | 10 Cr | 12.38 Cr | 20.78 Cr | 17.8 Cr |
| Packing Material Consumed | 17.82 Cr | 24.27 Cr | 26.08 Cr | 23.81 Cr |
| General and Administration Expenses | 25.58 Cr | 25.46 Cr | 22.94 Cr | 24.28 Cr |
| Insurance | 6.71 Cr | 7.39 Cr | 6.75 Cr | 7.24 Cr |
| Printing and stationery | 8.98 Lk | 16.26 Lk | 19.56 Lk | 21.04 Lk |
| Professional and legal fees | 3.89 Cr | 4.25 Cr | 3.31 Cr | 3.75 Cr |
| Traveling and conveyance | 26.12 Lk | 39.07 Lk | 67.73 Lk | 94.72 Lk |
| Selling and Distribution Expenses | 52.73 Cr | 65.68 Cr | 67.67 Cr | 50.95 Cr |
| Advertisement & Sales Promotion | 26.87 Lk | 35.33 Lk | 35.49 Lk | 1.08 Cr |
| Sales Commissions & Incentives | 11.21 Cr | 13.66 Cr | 16.91 Cr | 10.53 Cr |
| Freight and Forwarding | 35.32 Cr | 46.17 Cr | 40.93 Cr | 31.83 Cr |
| Handling and Clearing Charges | 5.93 Cr | 5.49 Cr | 5.58 Cr | 5.99 Cr |
| Miscellaneous Expenses | 3.67 Cr | 5.24 Cr | 5.74 Cr | 7.52 Cr |
| Bad debts /advances written off | 6 Lk | 75.58 Lk | 0 | 1.47 Cr |
| Total Expenditure | 1510.52 Cr | 1930.01 Cr | 2211.92 Cr | 1997.74 Cr |
| Other Income | 6.42 Cr | 4.77 Cr | 2.23 Cr | 4.18 Cr |
| Interest Received | 2.43 Cr | 65.22 Lk | 67.33 Lk | 2.4 Cr |
| Dividend Received | 2.97 Cr | 2.38 Cr | 11,000 | 11,000 |
| Operating Profit | 410.8 Cr | 325.94 Cr | 288.28 Cr | 273.36 Cr |
| Interest | 25.71 Cr | 23.05 Cr | 36.18 Cr | 33.21 Cr |
| Interest on Term Loan | 16.34 Cr | 11.7 Cr | 9.93 Cr | 5.78 Cr |
| Bank Charges etc | 3.1 Cr | 2.98 Cr | 3.65 Cr | 3.05 Cr |
| PBDT | 385.08 Cr | 302.89 Cr | 252.1 Cr | 240.15 Cr |
| Depreciation | 47.6 Cr | 47.39 Cr | 47.29 Cr | 47.67 Cr |
| Profit Before Taxation & Exceptional Items | 337.49 Cr | 255.5 Cr | 204.81 Cr | 192.48 Cr |
| Exceptional Income / Expenses | 22.48 Lk | 0 | 0 | 0 |
| Profit Before Tax | 337.71 Cr | 255.5 Cr | 204.81 Cr | 192.48 Cr |
| Provision for Tax | 80 Cr | 60.5 Cr | 52 Cr | 50.6 Cr |
| Current Income Tax | 84.5 Cr | 65.5 Cr | 53.25 Cr | 49.6 Cr |
| Deferred Tax | -4.5 Cr | -5 Cr | -1.25 Cr | 1 Cr |
| Profit After Tax | 257.71 Cr | 195 Cr | 152.81 Cr | 141.88 Cr |
| Consolidated Net Profit | 257.71 Cr | 195 Cr | 152.81 Cr | 141.88 Cr |
| Profit Balance B/F | 565.52 Cr | 704.26 Cr | 818.86 Cr | 947.13 Cr |
| Appropriations | 823.23 Cr | 899.26 Cr | 971.67 Cr | 1089.02 Cr |
| General Reserves | 25.77 Cr | 19.5 Cr | 15.28 Cr | 14.19 Cr |
| Other Appropriation | 69.9 Cr | 51.64 Cr | 0 | 13.32 Cr |
| Equity Dividend % | 25 | 10 | 10 | 10 |
| Earnings Per Share | 27.65 | 21.06 | 16.5 | 15.43 |
| Adjusted EPS | 27.65 | 21.06 | 16.5 | 15.43 |
CONSOLIDATED CASH FLOW FOR AARTI DRUGS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 369.01 Cr | 269.96 Cr | 224.18 Cr | 235.53 Cr |
| Adjustment | 68.6 Cr | 70.41 Cr | 85.15 Cr | 83.01 Cr |
| Changes In working Capital | -186.09 Cr | -187.35 Cr | -115.46 Cr | 102.78 Cr |
| Cash Flow after changes in Working Capital | 251.52 Cr | 153.01 Cr | 193.88 Cr | 421.32 Cr |
| Cash Flow from Operating Activities | 154.85 Cr | 69.64 Cr | 134.2 Cr | 358.92 Cr |
| Cash Flow from Investing Activities | -71.68 Cr | -148.86 Cr | -163.97 Cr | -223.65 Cr |
| Cash Flow from Financing Activitie | -81.13 Cr | 92.02 Cr | 16.54 Cr | -136.03 Cr |
| Net Cash Inflow / Outflow | 2.04 Cr | 12.8 Cr | -13.23 Cr | -76.07 Lk |
| Opening Cash & Cash Equivalents | 6.77 Cr | 8.81 Cr | 21.61 Cr | 7.5 Cr |
| Closing Cash & Cash Equivalent | 8.81 Cr | 21.61 Cr | 8.38 Cr | 6.74 Cr |
STANDALONE CASH FLOW FOR AARTI DRUGS LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 337.71 Cr | 255.5 Cr | 204.81 Cr | 192.48 Cr |
| Adjustment | 65.35 Cr | 66.76 Cr | 78.43 Cr | 77.68 Cr |
| Changes In working Capital | -161.21 Cr | -202.27 Cr | -66.13 Cr | 118.17 Cr |
| Cash Flow after changes in Working Capital | 241.85 Cr | 119.99 Cr | 217.11 Cr | 388.34 Cr |
| Cash Flow from Operating Activities | 154.08 Cr | 39.9 Cr | 162.28 Cr | 337.1 Cr |
| Cash Flow from Investing Activities | -68.93 Cr | -125.36 Cr | -131.14 Cr | -187.09 Cr |
| Cash Flow from Financing Activitie | -85.28 Cr | 84.11 Cr | -30.54 Cr | -148.81 Cr |
| Net Cash Inflow / Outflow | -13.42 Lk | -1.35 Cr | 60.86 Lk | 1.2 Cr |
| Opening Cash & Cash Equivalents | 2.98 Cr | 2.84 Cr | 1.49 Cr | 1.52 Cr |
| Closing Cash & Cash Equivalent | 2.84 Cr | 1.49 Cr | 2.1 Cr | 2.72 Cr |
CONSOLIDATED BALANCE SHEET FOR AARTI DRUGS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 93.2 Cr | 92.6 Cr | 92.6 Cr | 91.94 Cr |
| Equity - Authorised | 120 Cr | 120 Cr | 120 Cr | 120 Cr |
| Equity - Issued | 93.2 Cr | 92.6 Cr | 92.6 Cr | 91.94 Cr |
| Equity Paid Up | 93.2 Cr | 92.6 Cr | 92.6 Cr | 91.94 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | 820.22 Cr | 943.76 Cr | 1099.83 Cr | 1189.61 Cr |
| Capital Reserves | 6.28 Cr | 6.28 Cr | 6.28 Cr | 6.28 Cr |
| Profit & Loss Account Balance | 753.8 Cr | 878.75 Cr | 1020.53 Cr | 1155.25 Cr |
| General Reserves | 47.97 Cr | 45.27 Cr | 60.55 Cr | 14.89 Cr |
| Reserve excluding Revaluation Reserve | 820.22 Cr | 943.76 Cr | 1099.83 Cr | 1189.61 Cr |
| Shareholder's Funds | 913.42 Cr | 1036.36 Cr | 1192.43 Cr | 1281.55 Cr |
| Minority Interest | -1.68 Lk | -5.97 Lk | 23.33 Lk | 40.58 Lk |
| Secured Loans | 138.99 Cr | 129.93 Cr | 196.11 Cr | 271.76 Cr |
| Term Loans - Banks | 138.99 Cr | 129.93 Cr | 196.11 Cr | 543.52 Cr |
| Unsecured Loans | 8.57 Cr | 8.57 Cr | 8.57 Cr | 3.57 Cr |
| Loans - Others | 8.57 Cr | 8.57 Cr | 8.57 Cr | 3.57 Cr |
| Deferred Tax Assets / Liabilities | 77.13 Cr | 72.43 Cr | 70.97 Cr | 75.71 Cr |
| Deferred Tax Liability | 77.13 Cr | 72.43 Cr | 70.97 Cr | 75.71 Cr |
| Other Long Term Liabilities | 4.55 Cr | 2.05 Cr | 57.3 Lk | 1.08 Cr |
| Long Term Trade Payables | 6.34 Cr | 9.39 Cr | 12.27 Cr | 0 |
| Long Term Provisions | 21.67 Cr | 9.23 Cr | 7.27 Cr | 2.74 Cr |
| Total Non-Current Liabilities | 257.25 Cr | 231.6 Cr | 295.75 Cr | 354.86 Cr |
| Trade Payables | 329.97 Cr | 468.67 Cr | 480.27 Cr | 425.49 Cr |
| Sundry Creditors | 329.97 Cr | 468.67 Cr | 480.27 Cr | 425.49 Cr |
| Other Current Liabilities | 105.38 Cr | 111.33 Cr | 87.8 Cr | 151.21 Cr |
| Advances received from customers | 0 | 0 | 0 | 21.48 Cr |
| Interest Accrued But Not Due | 79.92 Lk | 1.02 Cr | 1.71 Cr | 2.21 Cr |
| Short Term Borrowings | 157.21 Cr | 356.34 Cr | 360.55 Cr | 214.7 Cr |
| Secured ST Loans repayable on Demands | 95.81 Cr | 342.64 Cr | 311.05 Cr | 172.2 Cr |
| Working Capital Loans- Sec | 95.81 Cr | 342.64 Cr | 311.05 Cr | 172.2 Cr |
| Short Term Provisions | 2.8 Cr | 3.71 Cr | 4.37 Cr | 4.13 Cr |
| Provision for Tax | 0 | 0 | 0 | 1.18 Cr |
| Provision for post retirement benefits | 2.8 Cr | 3.71 Cr | 0 | 0 |
| Total Current Liabilities | 595.36 Cr | 940.06 Cr | 932.98 Cr | 795.54 Cr |
| Total Liabilities | 1766.01 Cr | 2207.96 Cr | 2421.4 Cr | 2432.36 Cr |
| Gross Block | 1102.26 Cr | 1175.54 Cr | 1204.97 Cr | 1388.16 Cr |
| Less: Accumulated Depreciation | 436.86 Cr | 485.61 Cr | 528.74 Cr | 577.07 Cr |
| Net Block | 665.4 Cr | 689.93 Cr | 676.23 Cr | 811.09 Cr |
| Capital Work in Progress | 19.26 Cr | 76.74 Cr | 210.35 Cr | 225.23 Cr |
| Non Current Investments | 17.3 Cr | 19.48 Cr | 18.8 Cr | 19.97 Cr |
| Long Term Investment | 17.3 Cr | 19.48 Cr | 18.8 Cr | 19.97 Cr |
| Unquoted | 17.3 Cr | 19.48 Cr | 18.8 Cr | 19.97 Cr |
| Long Term Loans & Advances | 7.26 Cr | 28.44 Cr | 23.67 Cr | 19.7 Cr |
| Total Non-Current Assets | 709.22 Cr | 814.58 Cr | 929.05 Cr | 1111.64 Cr |
| Unquoted | 17.3 Cr | 19.48 Cr | 18.8 Cr | 19.97 Cr |
| Inventories | 415 Cr | 525.94 Cr | 516.29 Cr | 485.89 Cr |
| Raw Materials | 199.32 Cr | 221.62 Cr | 196.85 Cr | 183.28 Cr |
| Work-in Progress | 112.42 Cr | 162.53 Cr | 172.82 Cr | 128.13 Cr |
| Finished Goods | 89.49 Cr | 125.47 Cr | 116.93 Cr | 136.11 Cr |
| Packing Materials | 3.71 Cr | 5.62 Cr | 4.78 Cr | 5.19 Cr |
| Stores and Spare | 10.07 Cr | 10.63 Cr | 15.31 Cr | 20.26 Cr |
| Sundry Debtors | 555.23 Cr | 749.9 Cr | 864.84 Cr | 704.55 Cr |
| Debtors more than Six months | 6.87 Cr | 28.62 Cr | 34.62 Cr | 43.34 Cr |
| Debtors Others | 551.85 Cr | 725.56 Cr | 834.18 Cr | 664.18 Cr |
| Cash and Bank | 9.78 Cr | 22.33 Cr | 8.96 Cr | 9.43 Cr |
| Cash in hand | 29.95 Lk | 24.33 Lk | 28.24 Lk | 26.17 Lk |
| Balances at Bank | 7.93 Cr | 21.56 Cr | 7.8 Cr | 7.12 Cr |
| Other Current Assets | 2.44 Cr | 69.83 Lk | 69.81 Lk | 3.23 Cr |
| Prepaid Expenses | 0 | 0 | 0 | 2.78 Cr |
| Short Term Loans and Advances | 74.35 Cr | 94.5 Cr | 101.56 Cr | 117.61 Cr |
| Advances recoverable in cash or in kind | 20.25 Cr | 23.48 Cr | 16.35 Cr | 13.54 Cr |
| Total Current Assets | 1056.8 Cr | 1393.37 Cr | 1492.35 Cr | 1320.72 Cr |
| Net Current Assets (Including Current Investments) | 461.44 Cr | 453.32 Cr | 559.37 Cr | 525.18 Cr |
| Total Assets | 1766.01 Cr | 2207.96 Cr | 2421.4 Cr | 2432.36 Cr |
| Contingent Liabilities | 151.02 Cr | 180.15 Cr | 193.84 Cr | 248.95 Cr |
| Total Debt | 344.38 Cr | 538.34 Cr | 606.52 Cr | 562.42 Cr |
| Book Value | 98.01 | 111.92 | 128.77 | 0 |
| Adjusted Book Value | 98.01 | 111.92 | 128.77 | 139.4 |
STANDALONE BALANCE SHEET FOR AARTI DRUGS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 93.2 Cr | 92.6 Cr | 92.6 Cr | 91.94 Cr |
| Equity - Authorised | 120 Cr | 120 Cr | 120 Cr | 120 Cr |
| Equity - Issued | 93.2 Cr | 92.6 Cr | 92.6 Cr | 91.94 Cr |
| Equity Paid Up | 93.2 Cr | 92.6 Cr | 92.6 Cr | 91.94 Cr |
| Face Value | 10 | 10 | 10 | 10 |
| Total Reserves | 766.41 Cr | 879.57 Cr | 1021.7 Cr | 1083.27 Cr |
| Capital Reserves | 2.01 Cr | 2.01 Cr | 2.01 Cr | 2.01 Cr |
| Profit & Loss Account Balance | 704.26 Cr | 818.86 Cr | 947.13 Cr | 1052.31 Cr |
| General Reserves | 47.97 Cr | 45.27 Cr | 60.55 Cr | 14.89 Cr |
| Reserve excluding Revaluation Reserve | 766.41 Cr | 879.57 Cr | 1021.7 Cr | 1083.27 Cr |
| Shareholder's Funds | 859.61 Cr | 972.17 Cr | 1114.3 Cr | 1175.21 Cr |
| Secured Loans | 138.99 Cr | 109.76 Cr | 153.32 Cr | 234.69 Cr |
| Term Loans - Banks | 138.99 Cr | 109.76 Cr | 153.32 Cr | 469.37 Cr |
| Unsecured Loans | 8.57 Cr | 8.57 Cr | 8.57 Cr | 3.57 Cr |
| Loans - Others | 8.57 Cr | 8.57 Cr | 8.57 Cr | 3.57 Cr |
| Deferred Tax Assets / Liabilities | 74.97 Cr | 70.04 Cr | 68.37 Cr | 69.73 Cr |
| Deferred Tax Liability | 74.97 Cr | 70.04 Cr | 68.37 Cr | 69.73 Cr |
| Other Long Term Liabilities | 4.55 Cr | 2.05 Cr | 57.3 Lk | 1.08 Cr |
| Long Term Trade Payables | 6.31 Cr | 9.39 Cr | 12.27 Cr | 0 |
| Long Term Provisions | 22.12 Cr | 7.86 Cr | 7.11 Cr | 2.74 Cr |
| Total Non-Current Liabilities | 255.5 Cr | 207.67 Cr | 250.2 Cr | 311.81 Cr |
| Trade Payables | 293.04 Cr | 416.19 Cr | 419.01 Cr | 393.29 Cr |
| Sundry Creditors | 293.04 Cr | 416.19 Cr | 419.01 Cr | 393.29 Cr |
| Other Current Liabilities | 85.4 Cr | 82.85 Cr | 76.93 Cr | 113.8 Cr |
| Advances received from customers | 0 | 0 | 0 | 3.52 Cr |
| Interest Accrued But Not Due | 79.92 Lk | 1.02 Cr | 1.71 Cr | 2.21 Cr |
| Short Term Borrowings | 142.18 Cr | 353.05 Cr | 332.42 Cr | 173.47 Cr |
| Secured ST Loans repayable on Demands | 80.78 Cr | 339.35 Cr | 282.92 Cr | 130.97 Cr |
| Working Capital Loans- Sec | 80.78 Cr | 339.35 Cr | 282.92 Cr | 130.97 Cr |
| Short Term Provisions | 1.28 Cr | 2.59 Cr | 2.63 Cr | 4.03 Cr |
| Provision for Tax | 0 | 0 | 0 | 2.5 Cr |
| Provision for post retirement benefits | 1.28 Cr | 2.59 Cr | 0 | 0 |
| Total Current Liabilities | 521.89 Cr | 854.68 Cr | 830.99 Cr | 684.6 Cr |
| Total Liabilities | 1637.01 Cr | 2034.52 Cr | 2195.5 Cr | 2171.62 Cr |
| Gross Block | 1053.86 Cr | 1118.91 Cr | 1144.14 Cr | 1276.97 Cr |
| Less: Accumulated Depreciation | 423.34 Cr | 469.5 Cr | 509.66 Cr | 554.67 Cr |
| Net Block | 630.52 Cr | 649.42 Cr | 634.48 Cr | 722.29 Cr |
| Capital Work in Progress | 15.95 Cr | 59.62 Cr | 160.75 Cr | 221.62 Cr |
| Non Current Investments | 24.32 Cr | 28.03 Cr | 28.62 Cr | 29.97 Cr |
| Long Term Investment | 24.32 Cr | 28.03 Cr | 28.62 Cr | 29.97 Cr |
| Unquoted | 24.32 Cr | 28.03 Cr | 28.62 Cr | 29.97 Cr |
| Long Term Loans & Advances | 6.09 Cr | 24.26 Cr | 22.11 Cr | 16.71 Cr |
| Total Non-Current Assets | 676.88 Cr | 761.33 Cr | 845.96 Cr | 990.6 Cr |
| Unquoted | 24.32 Cr | 28.03 Cr | 28.62 Cr | 29.97 Cr |
| Inventories | 390.38 Cr | 488.46 Cr | 477.73 Cr | 441.77 Cr |
| Raw Materials | 186.52 Cr | 205.93 Cr | 183.53 Cr | 169.16 Cr |
| Work-in Progress | 107.82 Cr | 155.07 Cr | 163.73 Cr | 122 Cr |
| Finished Goods | 85.08 Cr | 115.78 Cr | 113.84 Cr | 128.8 Cr |
| Packing Materials | 88.35 Lk | 97.94 Lk | 1.22 Cr | 1.55 Cr |
| Stores and Spare | 10.07 Cr | 10.63 Cr | 15.31 Cr | 20.26 Cr |
| Sundry Debtors | 503.98 Cr | 711.64 Cr | 801.68 Cr | 643.96 Cr |
| Debtors more than Six months | 0 | 12.55 Cr | 23.7 Cr | 28.41 Cr |
| Debtors Others | 506.43 Cr | 701.98 Cr | 779.94 Cr | 617.81 Cr |
| Cash and Bank | 3.81 Cr | 2.21 Cr | 2.68 Cr | 3.82 Cr |
| Cash in hand | 23.65 Lk | 18.83 Lk | 24.07 Lk | 24.19 Lk |
| Balances at Bank | 2.02 Cr | 1.53 Cr | 1.56 Cr | 1.55 Cr |
| Other Current Assets | 2.44 Cr | 69.82 Lk | 69.81 Lk | 2.81 Cr |
| Prepaid Expenses | 0 | 0 | 0 | 2.36 Cr |
| Short Term Loans and Advances | 59.52 Cr | 70.18 Cr | 66.76 Cr | 88.67 Cr |
| Advances recoverable in cash or in kind | 19.22 Cr | 23.03 Cr | 14.94 Cr | 11.58 Cr |
| Total Current Assets | 960.13 Cr | 1273.19 Cr | 1349.53 Cr | 1181.02 Cr |
| Net Current Assets (Including Current Investments) | 438.23 Cr | 418.52 Cr | 518.54 Cr | 496.42 Cr |
| Total Assets | 1637.01 Cr | 2034.52 Cr | 2195.5 Cr | 2171.62 Cr |
| Contingent Liabilities | 151.02 Cr | 180.15 Cr | 191.39 Cr | 242.23 Cr |
| Total Debt | 329.35 Cr | 514.88 Cr | 533.08 Cr | 472.85 Cr |
| Book Value | 92.23 | 0 | 120.34 | 0 |
| Adjusted Book Value | 92.23 | 104.99 | 120.34 | 127.83 |
FINANCIAL RATIOS (CONSOLIDATED) FOR AARTI DRUGS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 30.09 | 22.14 | 17.96 | 18.65 |
| CEPS(Rs) | 35.44 | 27.54 | 23.4 | 24.26 |
| DPS(Rs) | 2.5 | 1 | 1 | 1 |
| Book NAV/Share(Rs) | 98.01 | 111.92 | 128.77 | 139.4 |
| Tax Rate(%) | 24.01 | 24.06 | 25.79 | 27.15 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 20.44 | 13.36 | 11.39 | 12.69 |
| EBIT Margin(%) | 18.34 | 11.81 | 9.62 | 10.81 |
| Pre Tax Margin(%) | 17.13 | 10.85 | 8.25 | 9.31 |
| PAT Margin (%) | 13.01 | 8.24 | 6.12 | 6.79 |
| Cash Profit Margin (%) | 15.33 | 10.25 | 7.98 | 8.82 |
| Performance Ratios | ||||
| ROA(%) | 16.78 | 10.32 | 7.19 | 7.07 |
| ROE(%) | 35.81 | 21.03 | 14.93 | 13.87 |
| ROCE(%) | 34.52 | 20.75 | 15.49 | 15.01 |
| Asset Turnover(x) | 1.29 | 1.25 | 1.17 | 1.04 |
| Sales/Fixed Asset(x) | 2.02 | 2.19 | 2.29 | 1.95 |
| Working Capital/Sales(x) | 4.67 | 5.49 | 4.86 | 4.81 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.5 | 0.46 | 0.44 | 0.51 |
| Receivable days | 88.41 | 95.71 | 108.5 | 113.27 |
| Inventory Days | 62.71 | 69 | 70.03 | 72.33 |
| Payable days | 68.71 | 90.28 | 95.49 | 102.98 |
| Valuation Parameters | ||||
| PER(x) | 23.09 | 19.37 | 18.81 | 23.27 |
| PCE(x) | 19.61 | 15.58 | 14.44 | 17.88 |
| Price/Book(x) | 7.09 | 3.83 | 2.62 | 3.11 |
| Yield(%) | 0.36 | 0.23 | 0.3 | 0.23 |
| EV/Net Sales(x) | 3.16 | 1.8 | 1.37 | 1.8 |
| EV/Core EBITDA(x) | 15.31 | 13.05 | 11.95 | 13.98 |
| EV/EBIT(x) | 17.23 | 15.27 | 14.26 | 16.61 |
| EV/CE(x) | 3.86 | 2.03 | 1.54 | 2.46 |
| M Cap / Sales | 3.01 | 1.6 | 1.15 | 1.58 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 19.31 | 15.49 | 9.14 | -6.9 |
| Core EBITDA Growth(%) | 66.63 | -22.7 | -9.38 | 4.24 |
| EBIT Growth(%) | 77.47 | -25.65 | -11.07 | 4.63 |
| PAT Growth(%) | 98.3 | -26.89 | -18.85 | 3.15 |
| EPS Growth(%) | -50.42 | -26.41 | -18.89 | 3.82 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.38 | 0.52 | 0.51 | 0.44 |
| Current Ratio(x) | 1.78 | 1.48 | 1.6 | 1.66 |
| Quick Ratio(x) | 1.08 | 0.92 | 1.05 | 1.05 |
| Interest Cover(x) | 15.07 | 12.29 | 7.04 | 7.22 |
| Total Debt/Mcap(x) | 0.05 | 0.14 | 0.19 | 0.14 |
FINANCIAL RATIOS (STANDALONE) FOR AARTI DRUGS LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 27.65 | 21.06 | 16.5 | 15.43 |
| CEPS(Rs) | 32.76 | 26.18 | 21.61 | 20.62 |
| DPS(Rs) | 2.5 | 1 | 1 | 1 |
| Book NAV/Share(Rs) | 92.23 | 104.99 | 120.34 | 127.83 |
| Tax Rate(%) | 23.69 | 23.68 | 25.39 | 26.29 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 21.12 | 14.27 | 11.45 | 11.87 |
| EBIT Margin(%) | 18.98 | 12.37 | 9.65 | 9.96 |
| Pre Tax Margin(%) | 17.64 | 11.35 | 8.2 | 8.49 |
| PAT Margin (%) | 13.46 | 8.66 | 6.12 | 6.26 |
| Cash Profit Margin (%) | 15.94 | 10.77 | 8.01 | 8.36 |
| Performance Ratios | ||||
| ROA(%) | 16.59 | 10.62 | 7.23 | 6.5 |
| ROE(%) | 34.79 | 21.29 | 14.65 | 12.39 |
| ROCE(%) | 33.35 | 20.82 | 15.38 | 13.7 |
| Asset Turnover(x) | 1.23 | 1.23 | 1.18 | 1.04 |
| Sales/Fixed Asset(x) | 1.88 | 2.07 | 2.21 | 1.87 |
| Working Capital/Sales(x) | 4.37 | 5.38 | 4.82 | 4.57 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.53 | 0.48 | 0.45 | 0.53 |
| Receivable days | 92.29 | 98.55 | 110.56 | 116.38 |
| Inventory Days | 66.5 | 71.25 | 70.59 | 74.02 |
| Payable days | 71.86 | 88.88 | 90.17 | 100.21 |
| Valuation Parameters | ||||
| PER(x) | 25.13 | 20.37 | 20.47 | 28.11 |
| PCE(x) | 21.21 | 16.39 | 15.63 | 21.04 |
| Price/Book(x) | 7.53 | 4.09 | 2.81 | 3.39 |
| Yield(%) | 0.36 | 0.23 | 0.3 | 0.23 |
| EV/Net Sales(x) | 3.55 | 1.99 | 1.46 | 1.97 |
| EV/Core EBITDA(x) | 16.56 | 13.76 | 12.69 | 16.31 |
| EV/EBIT(x) | 18.71 | 16.1 | 15.18 | 19.75 |
| EV/CE(x) | 4.15 | 2.2 | 1.67 | 2.7 |
| M Cap / Sales | 3.38 | 1.76 | 1.25 | 1.76 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 17.12 | 17.56 | 10.96 | -9.25 |
| Core EBITDA Growth(%) | 64.97 | -20.66 | -11.55 | -5.18 |
| EBIT Growth(%) | 72.47 | -23.35 | -13.48 | -6.35 |
| PAT Growth(%) | 89.95 | -24.34 | -21.63 | -7.15 |
| EPS Growth(%) | -52.51 | -23.84 | -21.63 | -6.48 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.38 | 0.53 | 0.48 | 0.4 |
| Current Ratio(x) | 1.84 | 1.49 | 1.62 | 1.73 |
| Quick Ratio(x) | 1.09 | 0.92 | 1.05 | 1.08 |
| Interest Cover(x) | 14.13 | 12.08 | 6.66 | 6.8 |
| Total Debt/Mcap(x) | 0.05 | 0.13 | 0.17 | 0.12 |
SHARE HOLDING PATTERN FOR AARTI DRUGS LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 59.98 | 59.77 | 59.66 | 59.58 | 58.70 | 58.56 | 57.47 | 57.13 | 55.67 | 55.64 |
| FII % | 2.07 | 1.94 | 1.90 | 1.94 | 1.97 | 2.33 | 2.10 | 2.56 | 2.95 | 2.50 |
| DII % | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.83 | 1.57 | 1.50 |
| Public % | 35.19 | 35.13 | 34.54 | 34.39 | 34.62 | 33.79 | 35.17 | 34.31 | 34.02 | 34.02 |
PEER COMPARISON FOR AARTI DRUGS LIMITED
CORPORATE ACTIONS FOR AARTI DRUGS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 17-Oct-2024 | Board Meeting - Quarterly Results | 24-Oct-2024 |
| BSE 21-Aug-2024 | Board Meeting - Buy Back of Shares | 26-Aug-2024 |
| BSE 19-Jul-2024 | Board Meeting - Audited Results & Quarterly Results | 26-Jul-2024 |
| BSE 26-Apr-2024 | Board Meeting - Audited Results | 03-May-2024 |
| BSE 06-Feb-2024 | Dividend - Rs.1.0000 per share(10%)Interim Dividend | |
| BSE 17-Jan-2024 | Board Meeting - Quarterly Results & Interim Dividend | 24-Jan-2024 |
| BSE 12-Oct-2023 | Board Meeting - Quarterly Results & Audited Results | 19-Oct-2023 |
| BSE 14-Jul-2023 | Board Meeting - Audited Results & Quarterly Results & Buy Back of Shares | 21-Jul-2023 |
| BSE 24-Apr-2023 | Board Meeting - Audited Results | 29-Apr-2023 |
| BSE 08-Feb-2023 | Dividend - Rs.1.0000 per share(10%)Interim Dividend | |
| BSE 20-Jan-2023 | Board Meeting - Quarterly Results & Interim Dividend | 27-Jan-2023 |
| BSE 13-Oct-2022 | Board Meeting - Quarterly Results | 20-Oct-2022 |
| BSE 21-Jul-2022 | Board Meeting - Quarterly Results | 27-Jul-2022 |
| BSE 02-May-2022 | Board Meeting - Audited Results | 09-May-2022 |
| BSE 09-Feb-2022 | Dividend - Rs.1.0000 per share(10%)Interim Dividend | |
| BSE 25-Jan-2022 | Board Meeting - Audited Results & Interim Dividend | 31-Jan-2022 |
| BSE 21-Oct-2021 | Board Meeting - Quarterly Results | 27-Oct-2021 |
CORPORATE ANNOUNCEMENTS FOR AARTI DRUGS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 30-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Credit Rating Credit Rating |
| BSE 26-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper publication of Financial Results |
| BSE 25-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome Q2 and H1 FY25 Earning concall transcript |
| BSE 24-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Investor Presentation Q2 and FY25 Investor Presentation |
| BSE 24-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Press Release / Media Release Q2 and H1 FY25 Business and Financial Performance |
| BSE 24-Oct-2024 | Outcome FILE | Financial Results For The Quarter And Half Year Ended September 30 2024 Financial Results for the quarter and half year ended September 30 2024 |
| BSE 18-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate |
| BSE 17-Oct-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Earning conference call |
| BSE 17-Oct-2024 | Intimation FILE | Board Meeting Intimation for Financial Results For The Quarter And Half Year Ended September 30 2024 AARTI DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve Audited financial results for the quarter and half year ended September 30 2024 |
| BSE 11-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate |
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 |
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 |
| BSE 09-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate |
| BSE 03-Oct-2024 | General Announcements FILE | Receipt Of GMP Certificate From UK-MHRA For Manufacturing Facility Of Subsidiary - Pinnacle Life Science Private Limited Located At Baddi Himachal Pradesh Receipt of GMP Certificate |
| BSE 27-Sep-2024 | General Announcements FILE | Completion Of Extinguishment Of Equity Shares In Connection With The Buy-Back Completion of Extinguishment of Equity shares in connection with the Buy-back |
| BSE 26-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Post Buyback Public Announcement Post Buyback Public Announcement |
| BSE 26-Sep-2024 | Intimation FILE | Closure of Trading Window Intimation of Closure of Trading window |
| BSE 26-Sep-2024 | General FILE | Post Buyback Public Announcement Inga Ventures Pvt Ltd ("Manager to the Buyback") has submitted to BSE a copy of Post Buyback public announcement for the attention of Equity Shareholders / Beneficial owners of Equity Shares of Aarti Drugs Ltd ("Target Company"). |
| BSE 25-Sep-2024 | General Announcements FILE | Clarification On Announcement Dated Sept 20 2024 .On USFDA Inspection At API Manufacturing Facility Of The Company Clarification on announcement dated Sept 20 2024 on USFDA inspection at API manufacturing facility of the Company |
| BSE 20-Sep-2024 | General Announcements FILE | United States Food And Drug Administration ('US FDA') Inspection US FDA inspection at API manufacturing faility of our Company located at Plot No E-22 MIDC Tarapur Maharashtra |
| BSE 20-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Directorate Re-appointment of Directors in the 39th AGM |
| BSE 20-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Scrutinizers Report and Voting Results of 39th AGM |
| BSE 20-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Investor Presentation Presentation made to the shareholders at the 39th AGM |
| BSE 20-Sep-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM Proceedings of 39th Annual General Meeting |
| BSE 18-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation to issue of duplicate share certificate |
| BSE 17-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Advertisement of extension of closing date of buyback |
| BSE 17-Sep-2024 | General FILE | Updates on Buyback offer Inga Ventures Pvt. Ltd ("Manager to the Buyback") has submitted to BSE a copy of Addendum to Letter of Offer for Buyback of Equity Shares of Aarti Drugs Ltd. |
| BSE 16-Sep-2024 | Outcome FILE | Corporate Action-Updates on Buy back Extension in Buyback offer period |
| BSE 16-Sep-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share certificate |
| BSE 12-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation Intimation of Analyst Meet |
INSIDER TRADING FOR AARTI DRUGS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 31-Mar-2022 31-Mar-2022 | Buy Market | 53,500 @ 0.00 (0.06 %) | ALCHEMIE FINSERV PVT LTD |
| BSE 31-Mar-2022 31-Mar-2022 | Buy Market | 14,000 @ 0.00 (0.01 %) | Harshit Manilal Savla |
| BSE 31-Mar-2022 31-Mar-2022 | Buy Market | 50,000 @ 0.00 (0.05 %) | Prakash Moreshwar Patil |
| BSE 31-Mar-2022 31-Mar-2022 | Buy Market | 11,000 @ 0.00 (0.01 %) | Seema Harshit Savla |
| BSE 31-Mar-2022 31-Mar-2022 | Buy Market | 25,000 @ 0.00 (0.02 %) | Harit Pragji Shah |
| BSE 31-Mar-2022 31-Mar-2022 | Sell Market | 164,500 @ 0.00 (0.17 %) | Renil Rajendra Gogri |
| BSE 28-Mar-2022 28-Mar-2022 | Sell Market | 180,615 @ 0.00 (0.20 %) | Renil Rajendra Gogri |
| BSE 28-Mar-2022 28-Mar-2022 | Buy Market | 120,000 @ 0.00 (0.13 %) | RASHESH CHANDRAKANT GOGRI |
| BSE 28-Mar-2022 28-Mar-2022 | Buy Market | 70,000 @ 0.00 (0.07 %) | ALCHEMIE FINSERV PVT LTD |
| BSE 02-Mar-2022 02-Mar-2022 | Buy Market | 609 @ 0.00 (0.01 %) | Arun Moreshwar Patil |
| BSE 24-Nov-2021 24-Nov-2021 | Buy Market | 20 @ 0.00 (0.00 %) | Uday Moreshwar Patil |
| BSE 01-Dec-2021 01-Dec-2021 | Buy Market | 500 @ 0.00 (0.00 %) | Uday Moreshwar Patil |
| BSE 20-Dec-2021 20-Dec-2021 | Buy Market | 500 @ 0.00 (0.00 %) | Uday Moreshwar Patil |
| BSE 28-Feb-2022 28-Feb-2022 | Buy Market | 500 @ 0.00 (0.00 %) | Uday Moreshwar Patil |
| BSE 15-Feb-2022 15-Feb-2022 | Buy Market | 8,600 @ 0.00 (0.01 %) | Prakash Moreshwar Patil |
| BSE 30-Dec-2021 30-Dec-2021 | Sell Market | 10,000 @ 0.00 (0.01 %) | Safechem Enterprises Pvt Ltd |
| BSE 29-Dec-2021 29-Dec-2021 | Sell Market | 71,258 @ 0.00 (0.08 %) | Safechem Enterprises Pvt Ltd |
| BSE 27-Dec-2021 27-Dec-2021 | Sell Market | 13,120 @ 0.00 (0.01 %) | Safechem Enterprises Pvt Ltd |
| BSE 21-Dec-2021 21-Dec-2021 | Buy Market | 200 @ 0.00 (0.00 %) | Prakash Moreshwar Patil |
| BSE 22-Dec-2021 22-Dec-2021 | Sell Market | 1,917 @ 0.00 (0.00 %) | Safechem Enterprises Pvt Ltd |
| BSE 23-Dec-2021 23-Dec-2021 | Sell Market | 8,705 @ 0.00 (0.01 %) | Safechem Enterprises Pvt Ltd |
| BSE 24-Dec-2021 24-Dec-2021 | Sell Market | 45,000 @ 0.00 (0.05 %) | Safechem Enterprises Pvt Ltd |
| BSE 30-Nov-2021 30-Nov-2021 | Buy Market | 19,200 @ 0.00 (0.03 %) | Prakash Moreshwar Patil |
| BSE 01-Dec-2021 01-Dec-2021 | Buy Market | 10,741 @ 0.00 (0.01 %) | Prakash Moreshwar Patil |
| BSE 30-Sep-2021 30-Sep-2021 | Sell Market | 19,647 @ 0.00 (0.02 %) | Safechem Enterprises Pvt Ltd |
BULK BLOCK DEALS FOR AARTI DRUGS LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY AARTI DRUGS LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 04-Feb-2025 | INTERIM DIVIDEND | 1 |
| 06-Feb-2024 | INTERIM DIVIDEND | 1 |
| 08-Feb-2023 | INTERIM DIVIDEND | 1 |
| 09-Feb-2022 | INTERIM DIVIDEND | 1 |
| 03-Nov-2020 | INTERIM DIVIDEND | 2.5 |
SPLIT / BONUS BY AARTI DRUGS LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
